Browse Categories

2 results match your criteria: "8University of Alabama at Birmingham[Affiliation]"

  • Page 1 of 1

What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.

J Natl Compr Canc Netw

June 2020

8University of Alabama at Birmingham, Birmingham, Alabama.

Eric J Roeland Kathryn J Ruddy Thomas W LeBlanc Ryan D Nipp Gary Binder

Background: Clinician adherence to antiemetic guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) caused by highly emetogenic chemotherapy (HEC) remains poorly characterized. The primary aim of this study was to evaluate individual clinician adherence to HEC antiemetic guidelines.

Patients And Methods: A retrospective analysis of patients receiving HEC was conducted using the IBM Watson Explorys Electronic Health Record Database (2012-2018).

View Article and Find Full Text PDF
Similar Publications

Acute myeloid leukemia, version 2.2013.

J Natl Compr Canc Netw

September 2013

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 5Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 6Stanford Cancer Institute; 7Massachusetts General Hospital Cancer Center; 8University of Alabama at Birmingham Comprehensive Cancer Center; 9UCSF Helen Diller Family Comprehensive Cancer Center; 10Moffitt Cancer Center; 11UNMC Eppley Cancer Center at The Nebraska Medical Center; 12The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 13St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 14Fox Chase Cancer Center; 15Duke Cancer Institute; 16The University of Texas MD Anderson Cancer Center; 17Huntsman Cancer Institute at the University of Utah; 18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 19Dana-Farber Cancer Institute; 20Vanderbilt-Ingram Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.

Margaret R O'Donnell Martin S Tallman Camille N Abboud Jessica K Altman Frederick R Appelbaum

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL.

View Article and Find Full Text PDF
Similar Publications
Privacy Policy Site Map

© LitMetric 2024. All rights reserved.